2024-09-03 - Analysis Report
## JNJ Stock Analysis Report

**Company Overview:** Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer goods company.

**Performance Analysis:**

**1.  Return Rate Comparison:**

*   **JNJ Cumulative Return:** 19.88%
*   **S&P 500 (VOO) Cumulative Return:** 89.66%
*   **Return Difference:** -69.78%
*   **Relative Divergence:** 12.84% (This means that JNJ's performance is currently in the 12.84th percentile of its historical performance compared to the S&P 500).

**2.  Recent Price Movements:**

*   **Closing Price:** $165.86
*   **5-day Moving Average:** $164.31
*   **20-day Moving Average:** $161.22
*   **60-day Moving Average:** $154.17

**3.  Technical Indicators:**

*   **RSI:** 74.35 (This indicates that JNJ is currently in overbought territory, suggesting potential for a short-term correction).
*   **PPO:** 0.09 (A positive value indicates that the 12-period moving average is above the 26-period moving average, suggesting bullish momentum).
*   **Delta_Previous_Relative_Divergence:** -9.44 (This indicates a recent short-term decline in relative divergence, suggesting a potential slowdown in momentum).
*   **Expected Return:** 11.93% (This is the estimated potential return for a 5-year investment).

**4.  Recent Earnings & Forecast:**

| Date      | EPS      | Revenue      |
|-----------|----------|--------------|
| 2024-07-25 | 1.95     | 22.45 B$     |
| 2024-05-01 | 1.35     | 21.38 B$     |
| 2024-02-16 | 1.68     | 21.39 B$     |
| 2023-10-27 | 10.32    | 21.35 B$     |
| 2024-02-16 | 10.32    | 21.35 B$     |

The most recent earnings report (2024-07-25) showed an EPS of 1.95, beating the analysts' estimates. This indicates positive earnings performance for the quarter. However, revenue growth was relatively flat, suggesting a potential slowing down in sales.

**Overall Analysis:**

JNJ's stock price has lagged behind the S&P 500 in recent years, despite its strong earnings and consistent dividend payments.  While the company's recent earnings beat expectations, the relatively flat revenue growth suggests a potential slowdown in momentum.  The technical indicators point to a short-term overbought condition, which could result in some price correction. However, the long-term growth prospects for JNJ remain solid, particularly considering its strong dividend yield and its position in the healthcare industry. Investors may want to consider this information when making investment decisions. 
